Insulet Stock Down 21.9% on Weaker 2026 Revenue Outlook
Insulet reported disappointing 2026 revenue outlook, citing weaker Type 2 retention. Analysts have slashed their forecasts and downgraded the company. Key analysts including JPMorgan, Wells Fargo, and Raymond James, have cut their ratings.
PODD shares fell 21.9% after Insulet cut its 2026 revenue outlook, even though the company beat Q2 estimates on both revenue and earnings.
The drop shows how much weight the market puts on forward guidance over a beaten quarter when the miss traces to a core growth driver. Insulet's growth story has leaned heavily on expanding Omnipod into the Type 2 diabetes market, so a stumble there raises questions about the durability of that expansion.
Q2 revenue came in at $801.7 million, up 23.5% year over year and ahead of Street estimates, with adjusted EPS of $1.66 beating the $1.45 consensus. But management lowered full-year 2026 revenue guidance to $3.25 billion to $3.30 billion from a prior $3.28 billion to $3.33 billion, below Wall Street's $3.32 billion estimate, and guided Q3 below consensus as well. CEO Ashley McEvoy acknowledged the company should have identified weaker retention and utilization among Type 2 patients sooner. JPMorgan downgraded the stock to Neutral from Overweight and Wells Fargo cut it to Equal Weight from Overweight, while Oppenheimer moved its rating to Market Perform from Outperform.
The setup leaves Insulet needing to show it can fix Type 2 retention without derailing the broader Omnipod rollout. Investors may want to watch the next quarter's Type 2 cohort data and whether additional analysts follow with downgrades or hold their ratings.
Related Stocks
Powered by SentiSense - Intelligent Market Analysis